Provided by Tiger Fintech (Singapore) Pte. Ltd.

Dyne Therapeutics, Inc.

8.28
-1.1400-12.10%
Post-market: 8.280.00000.00%16:57 EDT
Volume:2.60M
Turnover:21.78M
Market Cap:936.64M
PE:-2.46
High:9.40
Open:9.09
Low:8.15
Close:9.42
Loading ...

Company Profile

Company Name:
Dyne Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2017
Employees:
191
Office Location:
1560 Trapelo Road,Waltham,Massachusetts,United States
Zip Code:
02451
Fax:
781 786 8866
Introduction:
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Directors

Name
Position
Jason Rhodes
Director and Chairman of the Board
Joshua Brumm
Chief Executive Officer, President and Director
Catherine Stehman Breen
Director
David Lubner
Director
Dirk Kersten
Director
Edward Hurwitz
Director
Lawrence Klein
Director

Shareholders

Name
Position
Joshua Brumm
Chief Executive Officer, President and Director
Susanna High
Chief Operating Officer
Oxana Beskrovnaya
Senior Vice President, Head of Research
Jonathan McNeill
Vice President, Business Development
Richard Scalzo
Vice President of Accounting and Administration
Romesh Subramanian
Chief Scientific Officer